

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

I. CLAIM STATUS AND AMENDMENTS

Claims 1-26 were pending in this application when last examined.

Claims 19-24 were examined on the merits and stand rejected.

Claims 1-18, 25 and 26 were withdrawn as non-elected subject matter.

Claims 19, 21 and 23 are amended to recite the limitation of claim 15. Further, such claims have been amended to recite particular cancers. Support for this amendment can be found on page 14, lines 9-29, of the specification as filed. Claim 19 is further amended to recite "pharmaceutically acceptable carrier." Support can be found in Claim 18 as filed. Claims 20, 22 and 24 are cancelled without prejudice or disclaimer thereto.

Thus, no new matter has been added.

II. FOREIGN PRIORITY

The Examiner is respectfully requested to fully acknowledge the claim for foreign priority by checking the appropriate boxes in 12(a)(1-3) in the next Office Action.

III. 112 REJECTIONS

On pages 2-3 of the Office Action, claims 19-24 were rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. Further, on pages 3-6 of the Office Action, claims 19-24 were rejected under 35 U.S.C. § 112, first paragraph, for not reasonably providing enablement for treatment and prevention of all forms of cancer. Finally, on page 6 of the Office Action, claims 19-24 were rejected under 35 U.S.C. § 112, second paragraph, as indefinite.

Applicants respectfully traverse these rejections as applied to the amended claims.

The claims have been amended to recite particular cancers as well as a particular genus of

compounds as recited in claim 15. Furthermore, the Declaration attached herewith contains experimental data for N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butynyl]-6-quinazolinyl}acrylamide, which is a compound encompassed by the amended claims. The attached Declaration by an inventor of the claimed invention shows that this compound is effective for treatment of pancreatic cancer, cervical cancer, colorectal cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer and ovarian cancer.

Furthermore, Applicants note that the specification is replete with examples of compounds encompassed by claim 15.

Finally, Applicants note that the term “prophylactic” has been deleted from the amended claims.

Thus, for the above-noted reasons, Applicants suggest that these 112 rejections, as applied to the amended claims, are untenable and should be withdrawn.

IV. ANTICIPATION REJECTIONS

On page 7 of the Office Action, Claims 19-24 were rejected under 35 U.S.C. § 102(b) as anticipated by Carter et al. Further, Claims 19-24 were rejected under 35 U.S.C. § 102(b) as anticipated by Bridges et al.

Applicants respectfully traverse these rejections as applied to the amended claims.

The claims have been amended to recite the compounds originally recited in claim 15. Thus, Applicants note that there is no indication in the Office Action that such compounds are recited in the above-noted references. Thus, these rejections are untenable and should be withdrawn.


CONCLUSION

In view of the foregoing amendments and remarks, the present application is in condition for allowance and early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Masao TANIHARA et al.

By: 

William R. Schmidt, II
Registration No. 58,327
Attorney for Applicants

WRS/lc
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 3, 2008

ATTACHMENTS

1. Declaration by Tsuyoshi SUZUKI, executed June 27, 2008.